Drug Trial Radar · NCT05667194
Phase 1 Trial of KH617
Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Dec 26, 2022
Primary completion
Sep 2030
Study completion Aug 2031
Sponsor
- Lead sponsor
- Sichuan Honghe Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.
Conditions
- Advanced Solid Tumors
Interventions
KH617Drug
KH617 is s freeze-dried powder injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: 90 weeks
- DLTTime frame: 90 weeks
- RP2DTime frame: 154 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Titan Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.